TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Short Interest Up 650.4% in March

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) was the recipient of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 2,550,000 shares, an increase of 650.4% from the March 15th total of 339,800 shares. Approximately 12.2% of the company’s shares are sold short. Based on an average daily volume of 6,980,000 shares, the short-interest ratio is presently 0.4 days.

TransCode Therapeutics Price Performance

RNAZ stock traded up $0.01 during midday trading on Monday, hitting $0.41. The stock had a trading volume of 1,606,873 shares, compared to its average volume of 1,867,996. The business has a 50-day moving average of $3.57 and a two-hundred day moving average of $183.95. TransCode Therapeutics has a 52-week low of $0.34 and a 52-week high of $66.33.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of TransCode Therapeutics in a research note on Thursday, March 13th.

About TransCode Therapeutics

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.